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Background. End-stage renal disease (ESRD) is an important cause of morbidity and mortality in patients with systemic lupus
erythematosus (SLE).Objectives. To analyze the outcome and prognostic factors of renal transplantation in patients with ESRD due
to SLE from January 1986 toDecember 2013 in a single center.Results. Fifty renal transplantationswere performed in 40 SLE patients
(32 female (80%), mean age at transplantation 36± 10.4 years). The most frequent lupus nephropathy was type IV (72.2%). Graft
failure occurred in a total of 15 (30%) transplantations and the causes of graft failure were chronic allograft nephropathy (𝑛 = 12),
acute rejection (𝑛 = 2), and chronic humoral rejection (1). The death-censored graft survival rates were 93.9% at 1 year, 81.5% at
5 years, and 67.6% at the end of study. The presence of deceased donor allograft (𝑃 = 0.007) and positive anti-HCV antibodies
(𝑃 = 0.001) negatively influence the survival of the renal transplant. The patient survival rate was 91.4% at the end of the study.
Recurrence of lupus nephritis in renal allograft was observed in one patient. Conclusion. Renal transplantation is a good alternative
for renal replacement therapy in patients with SLE. In our cohort, the presence of anti-HCV antibodies and the type of donor source
were related to the development of graft failure.
1. Introduction
Systemic lupus erythematosus (SLE) is the prototype of
systemic autoimmune disease characterized by widespread
immunologic abnormalities and multiorgan involvement
including the skin, joints, lungs, heart, central and peripheral
nervous system, and kidney [1]. In fact, SLE may be consid-
ered as a syndrome rather than a single disease [2].
Considering renal involvement, 40% of the SLE patients
have lupus nephritis at some stage of their disease [3].
However, the prevalence of lupus nephritis varies around
the world with higher rates observed in some ethnic groups,
including Mestizos [4], African American, Hispanics living
in the United States, and Asian compared with Caucasian [5].
Lupus nephritis is an important cause of morbidity
and mortality in patients with SLE [6–8]. Of the different
pathological classes, diffuse proliferative glomerulonephritis
(class IV) has the worst prognosis, and end-stage renal
disease (ESRD) develops in a range from 3.5 to 17% [5, 9–11].
Ethnicity,male sex, younger age, high activity histopathologic
degree, interstitial fibrosis, impaired renal function at pre-
sentation, arterial hypertension as well as delay in treatment,
and poor compliance are some of the unfavorable prognostic
factors for ESRD in patients with lupus nephritis [12].
Recent surveys indicate that renal transplantation is
associated with good outcomes in patients with ESRD due
to lupus nephritis that are, in general, similar to transplant
recipients with ESRD due to other causes [13, 14]. Of note,
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some factors of the recipient have been associated with
poor outcome such as the black race, the positivity of
anti-phospholipid antibodies (aPL), the peritoneal dialysis,
the poor clinical conditions at the time of transplantation,
and the poor treatment compliance [13, 14]. In addition,
longer pretransplantation dialysis period was associated with
more acute rejection in a series of Chinese SLE patients
[15]. Recurrent lupus nephritis after kidney transplantation
occurs in a range from 0% to 30% according to the clinical
or histopathologic definition [16–18] but graft loss occurs
because recurrent lupus nephritis is rare [13, 14, 19].
Theobjective of this studywas to analyze the outcome and
prognostic factors of renal transplantation in patients with
ESRD due to SLE from our center.
2. Methods
2.1. Patients. We examined the medical records of patients
diagnosed as having SLE whose cause of ESRD (defined as
the need of chronic dialysis therapy or kidney transplan-
tation) was primarily lupus nephritis, who required renal
transplantation from January 1986 to December 2013. All
patients have been systematically assessed at the Department
of AutoimmuneDiseases and the Department of Nephrology
and Renal Transplantation of Hospital Clinic. All patients
fulfilled four or more of the 1982 revised classification criteria
for SLE of the American College of Rheumatology [20]. In
all cases, histological class of lupus nephritis was defined
according to the International Society of Nephrology/Renal
Pathology Society (ISN/RPS) 2003 classification system
[21].
2.2. Variables. From the patients’ records, we have docu-
mented the following data: gender, age at onset of SLE, onset
of clinical renal disease, and time between SLE diagnosis
and lupus nephritis and between lupus nephritis and onset
of dialysis. Antinuclear antibodies and aPL status, including
anti-cardiolipin antibodies (aCL) and lupus anticoagulant
(LA), anti-hepatitis B (HBV) and C virus (HCV), and anti-
human immunodeficiency virus (HIV) antibodies, were also
collected. Finally, SLE treatment prior to ESRD, duration
and modalities of dialysis prior to transplantation, date of
transplantation, age at transplantation and time between
lupus nephritis and transplantation, donor source, post-
transplantation immunosuppressive therapy used (especially
the use of prednisone, mycophenolic acid, cyclosporine A,
and tacrolimus), follow-up time after transplantation, lupus
relapse rate and graft, and patient survival were recorded.
Regarding immunosuppressive treatment, it was the same for
SLE and no SLE patients. Cyclosporine A, tacrolimus, and
mycophenolic acid were used according to the transplant era.
Induction therapywith anti-lymphocytesantibodies was used
according to the anti-HLA immunological risk.
We determined flare-ups of lupus activity and recurrence
of lupus nephritis by clinical and laboratory variables. Graft
failure was defined as the need to restart chronic dialysis
therapy or retransplantation.
2.3. Statistical Analysis. Qualitative variables are shown by
frequency distributions. Quantitative variables are summa-
rized as a mean ± standard deviation (SD). Kolmogorov
Smirnov test was used for evaluation of normality. A com-
parison of demographic and clinical characteristics between
groups (i.e., graft failure and functioning graft) was per-
formed using Mann-Whitney 𝑈-test and for categorical data
Fisher’s exact test was used. Patient and graft survival rates
were calculated with Kaplan-Meier survival curves. Patient
deaths with a functioning graft were censored for the graft
survival analysis. All statistical tests were two sided and
assessed at 𝑃 = 0.05 significance level. Statistical analyses
were performed using SPSS software, version 20.0.
3. Results
In the above mentioned period, a total of 3274 renal trans-
plantations were performed in our hospital, 50 (1.5%) of
them in 40 SLE patients (32 female (80%)). Overall, 29
transplantations were from a deceased donor whereas 21 were
from living donor. In 34 (68%) cases, a first transplantation
was performed and in twelve (24%) and four (8%) cases, a
second and a third transplantation were performed, respec-
tively. The main demographic and clinical characteristics,
histological class of lupus nephritis, immunologic features,
and treatments are described in Table 1.
3.1. Renal Graft Survival Rates. The death-censored graft
survival rates were 93.9% at 1 year, 81.5% at 5 years, and
67.6% at the end of the study (Figure 1). Clinical recurrence
of lupus nephritis in renal allograft was observed in only
one patient in form of membranous glomerulonephritis and
chronic allograft nephropathy. Graft failure occurred in a
total of 15 (30%) transplantations and the causes of graft
failure were chronic allograft nephropathy (𝑛 = 12), acute
rejection (𝑛 = 2), and chronic humoral rejection (𝑛 = 1).
3.2. Patient Survival Rates. The patient survival rates were
97.9% at 1 and 5 years and 91.4% at the end of the study.
Four patients died at 17.6, 11, 10, and 9.4 years of the first
renal transplantation, respectively.Thefirst casewas awoman
who received three renal transplantations, dying as a result of
Pseudomona aeruginosa sepsis. The second deceased patient
was a woman with cirrhosis and HCV chronic infection who
received two renal transplantations, dying as a result of E. coli
sepsis. The third patient developed a coronary artery disease
and died as a complication of this pathology. Finally, the forth
onewas amanwho died because of a dilatedmyocardiopathy.
3.3. Comparison between Patients with Graft Failure versus
Those with Functioning Grafts. When patients with graft
failure versus functioning graft at time of the study were
compared, we did not find significant differences in gender,
age at SLE diagnosis, dialysis modality, and age at trans-
plantation (Table 2). Of note, time on dialysis was longer in
patients with graft failure (73.9 ± 60.6 versus 35.7 ± 35.4, 𝑃 =
0.011). Conversely, the mean elapsed time between diagnosis
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Table 1: Demographic and clinical characteristics, histological and
immunologic features, and treatments used in the cohort of SLE
transplanted patients.
Demographic characteristics
Gender female 32 (80%)
Ethnicity
Caucasians 38 (95%)
Hispanics 2 (5%)
Age at SLE diagnosis (years) 22.7 ± 10.5
Age at renal transplantation (years) 36 ± 10.4
Time between SLE diagnosis and lupus nephritis
(months) 28.4 ± 65.1
Time between lupus nephritis and onset of dialysis
(months) 68.8 ± 72.3
Time on dialysis (months) 50 ± 49.4
Time between diagnosis of lupus nephritis and
transplantation (months) 118 ± 69
Time of followup (months) 71.4 ± 41
Histological diagnosis at onset of lupus nephritis:
Type IV 26 (72%)
Type III 3 (8%)
Type II 2 (5%)
Type V 2 (5%)
Type VI 1 (3%)
Interstitial nephritis 1 (3%)
Thrombotic microangiopathy 1 (3%)
Unknown 4 (10%)
Number of transplantations
First transplantation 34 (68%)
Second transplantation 12 (24%)
Third transplantation 4 (8%)
Donor source
Cadaveric donor 29 (58%)
Living donor 21 (42%)
HLA identical siblings 4 (19%)
Other genetically related 13 (62%)
Unrelated donors 4 (19%)
Immunologic features at renal transplantation
Antinuclear antibodies 50 (100%)
Anti-dsDNA antibodies 30 (60%)
Anti-phospholipid antibodies 12 (63%)
Treatments
Cyclosporine/tacrolimus 19/27
Azathioprine/mycophenolic acid 6/38
Sirolimus 3
ATG/OKT3/Basiliximab/no induction 23/1/9/17
Graft failure (%) 15 (30%)
Quantitative variables are presented as mean ± standard deviation and
qualitative variables as number (percentage). Treatments are presented as
number of transplantations.
SLE: systemic lupus erythematosus; ATG: antithymocyte globulin; OKT3:
orthoclone.
of lupus nephritis and start of dialysis was higher in those
patients with functioning grafts (88.7 ± 80.6 versus 39.0 ±
45.5, 𝑃 = 0.038). Graft failure was significantly higher in
patients receiving a kidney from a deceased donor compared
to living donors (𝑃 = 0.007, OR 10.0, 95% confidence interval
[CI] 1.62–62.85) (Table 2).
As posttransplant immunosuppression therapy, all
patients received prednisone and different immunosuppres-
sive therapies (Table 2).The election of the different immuno-
suppressive treatment was related to the working protocol
used in this moment in nephrology and renal transplant unit.
Although the differences in the outcome could be related
to a multifactorial origin, the majority of patients with graft
failure were in the cyclosporine era. In fact, the majority of
renal transplantations with graft failure were transplanted
before 1998 (53% versus 17%; 𝑃 = 0.036).
No patient had antibodies against HIV. Positive anti-
HCV antibodies were detected in 22 (44%) patients; one
of them was simultaneously positive for hepatitis B virus
(chronic infection). The number of patients with HCV
positive serology was significantly higher in the group of
patients who had graft failure, whereas in 12 of them, the
transplant outcome was toward the graft failure. Studies of
association between graft loss and the presence of HCV
positive serology showed a positive association (𝑃 = 0.001,
OR 12.5 CI 95% [2.50–63.34]) (Table 2). When association
studies were performed considering the type of donor source
(deceased or living donor) and HCV positive serology, both
remained as statistical significant prognostic factor of graft
failure.
3.4. Retransplantation Cases. The retransplantation cases
were analyzed separately from the main group. Overall
16 additional transplantations were performed (7 from a
deceased donor and 9 from a living donor). In all cases, the
initial lupus nephropathy was type IV. There were 6 graft
failures whose causes were chronic allograft nephropathy
(𝑛 = 5) and acute rejection (𝑛 = 1). In one patient with
negative aPL and chronic allograft nephropathy, renal arterial
and venous thrombosis involving medium-sized vessel wall
were observed.
3.5. Anti-phospholipid Antibodies and Renal Transplantation.
Nineteen patients (48%) had at least two aPL determinations,
12 (63%) of them being positive (5 with IgG aCL plus LA,
4 with IgG aCL only, 2 with IgM aCL plus LA, and one
with LA plus IgM plus IgGaCL), and only two of them had
antiphospholipid syndrome. Within this group, one of the
patients that previously received two renal transplantations
suffered graft loss due to intraparenchymal graft thrombosis.
In another case, a patient suffered the loss of two consecutive
grafts due to thrombotic microangiopathy. In both patients,
previous studies were negative for aPL, starting to be positive
just before the third renal transplant.
4. Discussion
In the present study, we have found a graft survival rate of
93.9% at 1 year, 81.5% at 5 years, and 67.6% at the end of the
study and the patient survival rates were 97.9% at 1 and 5 years
and 91.4% at the end of the study. These observations are
similar to those reported in other recent studies from other
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Table 2: Comparison of demographic features, clinical characteristics and treatment between SLE patients with graft failure and functioning
graft.
Graft failure (𝑛 = 15) Functioning graft (𝑛 = 35) 𝑃
Gender female (%) 14 (93%) 27 (77%) 0.169
Age at diagnosis SLE (years) 22.4 ± 10 22.8 ± 11 0.758
Age at renal Tx (years) 41.3 ± 10.2 38.7 ± 12.0 0.280
Time SLE-nephritis (months) 17 ± 42.6 34.9 ± 75 0.412
Time nephritis dialysis (months) 39 ± 45.5 88.7 ± 80.6 0.038
Time on dialysis (months) 73.9 ± 60.6 35.7 ± 35.4 0.011
Time nephritis-Tx (months) 114.6 ± 64.2 120 ± 73.3 0.880
Dialysis before renal Tx (%):
HD 14 (93.3%) 19 (76.0%) 0.168
CAPD 2 (13.3%) 7 (28.0%) 0.251
HD and CAPD 1 (6.7%) 3 (12.0%) 0.516
Tx date (years) 1998 ± 7 2004 ± 6 0.036
Donor source (%):
Cadaveric 13 (86.7%) 16 (45.7%) 0.007
Living donor 2 (13.3%) 19 (54.3%) —
Immunosuppressive regimen at Tx (grafts) (%):
Cyclosporine A 10 (66.6%) 9 (25.7%) 0.006
Mycophenolic acid 8 (53%) 31 (88.6%) 0.003
Tacrolimus 4 (27%) 23 (66%) 0.012
Positive anti-HCV antibodies (patients) (%) 12 (80%) 10 (28.6%) 0.001
Positive aPL antibodies (%) 1 (6.7%) 11 (31.4%) 0.058
Quantitative variables are presented as mean ± standard deviation and qualitative variables as number (percentage).
SLE: systemic lupus erythematosus; Tx: transplantation; HD: hemodialysis; CAPD: continuous ambulatory peritoneal dialysis; HCV: hepatitis C virus; aPL:
anti-phospholipid antibodies.
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Figure 1: Death-censored graft survival rates at 1, 5, and 10 years.
single centers including patients from different ethnicities
[22–27]. The main cause of graft failure was chronic allograft
nephropathy, which is similar to data previously reported for
SLE patients and also for non-SLE transplant recipients [28].
Currently, graft and patient survival of SLE patients
undergoing renal transplantation are similar to those found
in renal transplant recipients from other causes. These con-
cepts are supported by the results of the European Transplant
Registry and by a cohort of patients in the United States
(United States Renal Data System) [13, 29]. However, other
authors describe different resultswith lower graft survival and
increased mortality in patients with SLE [30]. This difference
may be explained at least partly, by methodological differ-
ences between studies in terms of prospective or retrospective
design, inclusion criteria, control group, and different time
of renal transplantation or recruitment period. Moreover, a
retrospective study analyzed 8001 patients with SLE and renal
transplantation showed that graft and patients survival were
higher in those patients who received a preemptive renal
transplantation compared with those who were treated with
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hemodialysis previously (hazard ratio [HR] 0.69; 95% CI
0.55–0.86, 𝑃 < 0.01 versus HR 0.52; 95% CI 0.38–0.70, 𝑃 <
0.01, resp.) [31]. In fact, in the current series, time on dialysis
was significantly shorter in patients with functioning graft.
Thus, as in other diseases with ESRD, renal transplantation
is considered the procedure of choice for renal replacement
therapy in patients with SLE [31].
In our series, relapsing lupus nephritis was found only
in one case (2%). The recurrence rate of lupus nephritis
was reported initially to be around 1–4% [32, 33]. How-
ever, immunofluorescence and electron microscopy studies
performed in renal biopsies of SLE transplanted patients
detected a rate of recurrent lupus nephritis of 30% [19, 34, 35].
However, it does not seem to negatively affect allograft or
patient survival [19, 34]. Interestingly, Norby et al. [17] found
a recurrence of lupus nephritis in 54% of renal biopsies from
41 SLE patients with renal transplant. However, the majority
of them were subclinical in form of histological class I or II.
Of note, 83% of the transplanted kidneys presentedwith signs
of chronic allograft nephropathy, regardless of the presence
or absence of lupus nephritis. Similar results of recurrence
of lupus nephritis have been described in a Chinese kidney
transplant cohort of 32 SLE patients [22].
Our results showed that factors that negatively influenced
the survival of the renal transplant were the presence of
deceased donor allograft (𝑃 = 0.007), positive anti-HCV
antibodies (𝑃 = 0.001), and a longer time on dialysis before
transplantation (𝑃 = 0.011). In retrospective studies per-
formed on databases, the deceased donor allograft recipients
have worse outcomes compared with living allograft recip-
ients [30] and African American and Caucasian Americans
have similar allograft failure rates [36].
A particular feature of this series is the high number of
patients with HCV infection, mainly located in the group of
transplant failure, showing a significant positive association
with the lower graft survival (OR 12.5, 95% CI 2.50–63.34),
in the same manner as that described in non-SLE patients
[37, 38]. Recent evidence documents that the concomitant
HCV infection in patients with lupus nephritis is associated
with worse renal outcome, higher rate of progression to
ESRD, and reduced patient survival [39]. In a retrospective
study involving 1624 patients with positive serology for HCV
undergoing kidney transplant, Batty et al. [40] found a higher
mortality (HR 1.23; 95% CI 1.01–1.49, 𝑃 = 0.04) and higher
rate of hospitalization in patients positive for HCV compared
with patients serologically negative. A recent systematic
review collecting 18 series described the negative impact
of HCV infection in the outcome of renal transplantation,
with increased mortality (HR 1.69; 95% CI 1.33–1.97, 𝑃 <
0.0001) and graft loss (HR 1.56; 95% CI 1.22–2.004, 𝑃 <
0.0001) [41]. However, in the last two studies [40, 41], lupus
nephropathy was not specifically analyzed. Although the
intimate pathogenic mechanisms by which HCV induces
a negative impact on renal graft remain to be known,
there is some evidence attributing to plasmatic viremia and
anti-HCV antibodies themselves a possible pathogenic role
impairing the kidney function or inducing the development
of chronic nephropathy allograft [37, 42].
The reason why HCV recipients are overrepresented in
this cohort of patients is probably related to the high rate of
repeated transplantations. Twenty-two transplants in HCV
positive recipients were distributed between 13 patients: 5
patients with one, 7 patients with two, and one patient with
three transplants. By contrast within the 28 transplants in
HCV negative recipients, there were 26 patients with one
transplant and one patient with two transplants. Many of
those HCV positive patients initiated dialysis therapy before
the HCV screening test was available.
In our series, the use of mycophenolic acid, tacrolimus,
and negative aPL determinations seem to be related with
better renal graft survival, supporting the possible multifac-
torial origin of the improved performance. Moreover, thanks
to methodological advances in transplantation procedure,
the use of mycophenolic acid and tacrolimus in recent years
partly explain the significant differences found in our series,
thus, supporting the benefit of their use.
As shown in our series, coronary artery disease was one of
the causes associated with mortality in the outcome. Recent
studies demonstrate a reduction in cardiovascular risk with
the administration of fluvastatin in patients with lupus recip-
ients of kidney transplantation [43]. Two more patients died
because of sepsis, probably related to immunosuppressive
treatment.
Thrombotic events have been reported more frequently
in renal transplantation recipients with aPL worsening their
functional prognosis [14, 23]. In a recent study, the presence
of LA at the time of renal transplantation was associated
with a high rate of allograft nephropathy associated with
antiphospholipid syndrome and poor transplantation out-
comes [44]. In the current series, aPL determinations were
available in 19 patients, because the systematic screening
in the renal transplant unit was carried out only in recent
years. In the present series, the allograft failure was related to
thrombosis and thromboticmicroangiopathy associated with
the presence of aPL in two cases; therefore their detection as
well as their repetition in the time, despite their negativity,
should be recommended in the pretransplantation period.
Current study had some limitations.Due to the retrospec-
tive design of our analysis, some points such as the role of
activity of SLE in the graft failure or the role of sociodemo-
graphic and environmental factors such as educational level,
socioeconomic status, or smoking could not be analyzed.
Moreover, the limited number of SLE patients who received
kidney transplantation is the reason why some significant
associations should be considered with caution as indicated
by the wide range of confidence intervals. In the data
collected, the number of patients with aPL determinations
performed before or at the time of kidney transplantationwas
low; therefore the association between these antibodies and
the thrombotic complications was weak and not significant.
Renal transplantation is a good alternative for renal
replacement therapy in patients with SLE, but the existence of
HCV positive serology and a thrombotic disease associated
with the aPL could be related to the development of graft
failure. In our series, the patient and graft survival rates as
well as factors associated with these end points are similar to
that of ESRD caused by other diseases.
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